17 Jul 2020 --- Silibinin sourced from Euromed SA’s milk thistle extract and cannabidiol (CBD) are the latest ingredients to come under the microscope in the fight against the COVID-19 crisis. Silibinin, a key component of flavonoid silymarin, will be used in a clinical trial called SilCOVID19 for oncohematological patients diagnosed with COVID-19. Meanwhile, US researchers have early evidence that CBD may help reduce the cytokine storm and excessive lung inflammation that is killing many patients with COVID-19. Notably, they used a new model that could also open the door for further safe research of the novel coronavirus.